Founder and Chief Scientific Officer
Dr. Bhargava received Ph.D. from Indian Institute of Science, Bangalore, India. After post-doctoral studies with Professor Sherman Weissman at Yale University, Dr. Bhargava joined Bayer Corporation. At Bayer, he worked on target identification, target validation and assay development projects in osteoarthritis, osteoporosis and oncology therapeutic areas. Within oncology, he worked on various drug discovery projects including kinases, cytotoxics and hypoxia pathway inhibitors. Dr. Bhargava led cross functional, preclinical drug discovery project teams towards Phase I clinical trials. Dr. Bhargava has authored several peer-reviewed international scientific publications.